その他 |
[粒径]19-20μm
|
参考文献 |
[[Cosmo Reference Collection]] Fukushima A., et al. Engagement of 4-1BB inhibits the development of experimental allergic conjunctivitis in mice. J Immunol. 2005 Oct 15;175(8):4897-903. Fukushima A., et al. Roles of OX40 in the development of murineexperimental allergic conjunctivitis: exacerbation and attenuation bystimulation and blocking of OX40. Invest Ophthalmol Vis Sci. 2006 Feb;47(2):657-63. Fukushima A., et al. The interaction between ICOS and B7RP-1 is not required for the developmentof experimental murine allergic conjunctivitis. Biochem Biophys Res Commun. 2005 Dec 30;338(4):1726-31. Fukushima A., et al. TLR2 agonist ameliorates murine experimental allergic conjunctivitis by inducing CD4 positive T-cell apoptosis rather thanbyaffecting the Th1/Th2 balance. Biochem Biophys Res Commun. 2006 Jan 27;339(4):1048-55. Fukushima A., et al. Genetic background determines susceptibility to experimental immune-mediated blepharoconjunctivitis:comparison of Balb/c and C57BL/6 mice. Exp Eye Res. 2006 Feb;82(2):210-8. Fukushima A., et al. The immunization protocol determines whether endogenous interferon-gamma suppresses the infiltration ofeosinophils into the conjunctiva. Immunol Lett. 2005 Sep 15;100(2):189-94. Ishida W., et al. Adjuvants determine the contribution of basophils to antigen sensitization in vivo. Immunol Lett. 2011 Apr 30;136(1):49-54. Fukuda K., et al. Analysis of the interaction between IFN-gamma and IFN-gammaR in the effector phase of experimental murineallergic conjunctivitis. Immunol Lett. 2006 Nov 15;107(2):119-24. Epub 2006 Sep 8. Fukuda K., et al. T-cell Ig and mucin domain-containing protein (Tim)-2 regulates murine allergic conjunctivitis during the effectorphase. Immunol Lett. 2007 Jun 15;110(2):133-8. Ishida W., et al. Systemic overexpression of IFN-gamma and IL-5 exacerbates early phase reaction and conjunctival eosinophilia,respectively, in experimental allergic conjunctivitis. Br J Ophthalmol. 2009 Dec;93(12):1680-5. Fukushima A., et al. Role of VLA-4 in the development of allergic conjunctivitis in mice. Mol Vis. 2006 Apr 7;12:310-7. Fukushima A., et al. Depletion of thymus-derived CD4+CD25+ T cells abrogates the suppressive effects of alpha-galactosylceramide treatmentonexperimental allergic conjunctivitis. Allergol Int. 2008 Sep;57(3):241-6. Fukushima A., et al. Modulation of murine experimental allergic conjunctivitis by treatment with alpha-galactosylceramide.Immunol Lett. 2006 Sep 15;107(1):32-40. Sumi T.,etal. Differential contributions of B7-1 and B7-2 to the development of murine experimental allergic conjunctivitis. Immunol Lett. 2007 Jan 15;108(1):62-7. Fukushima A., et al. B7-H3 regulates the development of experimental allergic conjunctivitis inmice. Immunol Lett. 2007 Oct 31;113(1):52-7. Sumi T., et al. Activation of tumour-necrosis factor-related apoptosis-inducing ligand receptor enhances the severity of murine allergic conjunctivitis. Br J Ophthalmol. 2009 Jan;93(1):110-5. FukushimaA.,et al. Antibodies to T-cell Ig and mucin domain-containing proteins (Tim)-1 and -3 suppress the induction and progression ofmurine allergic conjunctivitis. Biochem Biophys Res Commun. 2007 Feb 2;353(1):211-6. Sumi T., et al. CD27 and CD70 donotplaya critical role in the development of experimental allergic conjunctivitis in mice. Immunol Lett. 2008 Aug 15;119(1-2):91-6. Fukushima A., et al. Notch ligand Delta-like4 inhibits the development of murine experimental allergic conjunctivitis.Immunol Lett. 2008 Dec 22;121(2):140-7. Fukushima A., et al. Participation of CD11b and F4/80 molecules in the conjunctival eosinophilia of experimental allergic conjunctivitis. Int Arch Allergy Immunol. 2010;151(2):129-36.
|
|
メーカー |
品番 |
包装 |
PSI
|
07673-1
|
1 G
|
※表示価格について
当社在庫 |
なし
|
納期目安 |
2週間程度
|
保存温度 |
常温
|
|